Bio-Rad Labs (BIO) Tops Q1 EPS by $2.21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Bio-Rad Reports First-Quarter 2021 Financial Results
April 29, 2021 4:15 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2021.
First-quarter 2021 net sales were $726.8 million, an increase of 27.1 percent compared to $571.6 million reported for the first quarter of 2020. On a currency-neutral basis, quarterly sales increased 23.4 percent compared to the same period in 2020. First-quarter gross margin was 55.1 percent compared to 55.5 percent during the first quarter in 2020.
Life Science segment net sales for the first quarter were $366.5 million, an increase of 61.3 percent compared to the... More
